Scancell to attend upcoming conferences

Scancell Holdings Plc

02 September 2024

 

2 September 2024

Scancell Holdings plc

("Scancell" or the "Company")

Scancell Announces its Attendance at Upcoming Conferences

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to confirm that it will be presenting at, and will also attend, several upcoming conferences and events in September, October and November 2024. Presentations at these high-profile conferences follow the significant recent progress that Scancell has made in both pre-clinical and clinical development.

These include:

·      ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit taking place in Boston, Massachusetts, USA from 9-10 September.

Mandeep Sehmi, Head of Business Development, will be attending the conference.

·      ESMO Congress 2024 taking place in Barcelona, Spain from 13-17 September

Dr Nermeen Varawalla, Chief Medical Officer, and Dr Robert Miller, Medical Director, will be attending the conference.

·      Vaccines & Immunotherapies Online Symposium taking place virtually on Thursday, 26 September.

Samantha Paston, Head of Translational Research, will be presenting.

Title: Phase 2 clinical trial, a DNA cancer vaccine, SCIB1, in patients with advanced unresectable melanoma receiving nivolumab + ipilimumab

Time: 4.20pm BST

·      Festival of Biologics taking place in Basel, Switzerland from 15-17 October.

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer, will be presenting.

Session Title: Therapeutic Vaccine Development

Title: Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination

Date and Time: Wednesday, 16 October at 5.30pm CEST

·      16^th Annual PEGS Europe taking place in Barcelona, Spain and virtually from 5-7 November.

Mireille Vankemmelbeke, Principal Scientist, will be presenting.

Session Title: Antibody-Based Cancer Therapies: Novel Targets

Title: Fucosyl-GM1: A Versatile Target for SCLC Therapy

Date and Time: Tuesday, 5 November at 5.05pm CEST

If you would like to arrange a meeting with management, please contact [e-mail].

-ENDS-

For further information, please contact:
Scancell Holdings plc	[phone]
Dr Jean-Michel Cosséry, Non-Executive Chairman
Professor Lindy Durrant, CEO
Panmure Liberum Limited (Nominated Advisor and Joint Broker)	[phone]
Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
WG Partners LLP (Joint Broker) David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby	[phone]
ICR Consilium	[phone]
Mary-Jane Elliott/Angela Gray/Lindsey Neville	[e-mail]

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END